Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bas W G van Rhijn

Showing results (21-30 of 215) with videos related to

Pageof 22
Sort By:
International Journal of Cancer|July 11, 2022
Reply to: Comments on "Neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer"Sarah M H Einerhand, Nick van Dijk, Michiel S van der Heijden, et al.
European Urology|October 9, 2022
Re: Neoadjuvant PD-L1 plus CTLA-4 Blockade in Patients with Cisplatin-ineligible Operable High-risk Urothelial CarcinomaSarah M H Einerhand, Jeroen van Dorp, Michiel S van der Heijden, et al.
The Journal of Pathology|September 19, 2002
Frequent FGFR3 mutations in urothelial papillomaBas W G van Rhijn, Rodolfo Montironi, Ellen C Zwarthoff, et al.
European Urology Open Science|October 8, 2021
Two Patients with Urachal Cancer with Multifocal Adenocarcinoma Recurrences in the Urothelium of the Prostatic and Penile UrethraLaura E Stokkel, Maurits L van Montfoort, Hester H van Boven, et al.
The Journal of Urology|August 22, 2025
Letter: Updates to Microhematuria: AUA/SUFU Guideline (2025)Shahrokh F Shariat, Bas W G van Rhijn, Christian Bolenz, et al.
Methods in Molecular Biology (Clifton, N.J.)|July 6, 2023
Considering the Effects of Modern Point-of-Care Urine Biomarker Assays in Follow-Up of Patients with High-Risk Non-muscle-Invasive Bladder CancerThorsten H Ecke, Natalya Benderska-Söder, Ekkehardt Bismarck, et al.
European Urology|March 24, 2004
Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapyBarthold Ph Schrier, Maarten P Hollander, Bas W G van Rhijn, et al.
Histopathology|August 18, 2016
Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathwayMichelle R Downes, Berber Weening, Bas W G van Rhijn, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 13, 2020
The comprehensive complication index is associated with a significant increase in complication severity between 30 and 90 days after radical cystectomy for bladder cancerMaximilian Haas, Toni Huber, Christoph Pickl, et al.
Urology Annals|June 23, 2020
A testosterone-producing Leydig cell tumor metastasis during hormonal treatment of prostate cancerLaura Stokkel, Henk G van der Poel, Sigrun I Langbein, et al.
Pageof 22

Showing results (21-30 of 215) with videos related to

Sort By:
Pageof 22
International Journal of Cancer|July 11, 2022
Reply to: Comments on "Neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer"Sarah M H Einerhand, Nick van Dijk, Michiel S van der Heijden, et al.
European Urology|October 9, 2022
Re: Neoadjuvant PD-L1 plus CTLA-4 Blockade in Patients with Cisplatin-ineligible Operable High-risk Urothelial CarcinomaSarah M H Einerhand, Jeroen van Dorp, Michiel S van der Heijden, et al.
The Journal of Pathology|September 19, 2002
Frequent FGFR3 mutations in urothelial papillomaBas W G van Rhijn, Rodolfo Montironi, Ellen C Zwarthoff, et al.
European Urology Open Science|October 8, 2021
Two Patients with Urachal Cancer with Multifocal Adenocarcinoma Recurrences in the Urothelium of the Prostatic and Penile UrethraLaura E Stokkel, Maurits L van Montfoort, Hester H van Boven, et al.
The Journal of Urology|August 22, 2025
Letter: Updates to Microhematuria: AUA/SUFU Guideline (2025)Shahrokh F Shariat, Bas W G van Rhijn, Christian Bolenz, et al.
Methods in Molecular Biology (Clifton, N.J.)|July 6, 2023
Considering the Effects of Modern Point-of-Care Urine Biomarker Assays in Follow-Up of Patients with High-Risk Non-muscle-Invasive Bladder CancerThorsten H Ecke, Natalya Benderska-Söder, Ekkehardt Bismarck, et al.
European Urology|March 24, 2004
Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapyBarthold Ph Schrier, Maarten P Hollander, Bas W G van Rhijn, et al.
Histopathology|August 18, 2016
Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathwayMichelle R Downes, Berber Weening, Bas W G van Rhijn, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 13, 2020
The comprehensive complication index is associated with a significant increase in complication severity between 30 and 90 days after radical cystectomy for bladder cancerMaximilian Haas, Toni Huber, Christoph Pickl, et al.
Urology Annals|June 23, 2020
A testosterone-producing Leydig cell tumor metastasis during hormonal treatment of prostate cancerLaura Stokkel, Henk G van der Poel, Sigrun I Langbein, et al.
Pageof 22